- Published at
- by manilatimes.net
neutral
neutral
News for Sensei Biotherapeutics, Inc. (SNSE)
- Published at
- by gurufocus.com
neutralneutralSensei Biotherapeutics (SNSE) Reports Annual Loss and Decline in Cash Reserves
Sensei Biotherapeutics (SNSE) disclosed a fiscal year GAAP earnings per share (EPS) of -$1.20. The company's cash, cash equivalents, and marketable securities f- Published at
- by gurufocus.com
negativenegativeSensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant ”hot” tumor patient popul- Published at
- by benzinga.com
mixedmixedWhy Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Alta Equipment Group (NYSE:ALTG), Argan (NYSE:AGX)
Shares of Braze, Inc. BRZE rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issue...- Published at
- by benzinga.com
mixedmixedUS Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets' - Braze (NASDAQ:BRZE), AAR (NYSE:AIR)
U.S. stock futures fell on Friday after two consecutive days of decline on Wednesday and Thursday. Futures of benchmark indices were lower.- Published at
- by rttnews.com
mixedmixedPRTG Soars On Mesothelioma Data, NVNO Awaits FDA Decision, CureVac Jumps On Patent News
Shares of Portage Biotech Inc. (PRTG) were up over 100% in after-hours trading on Thursday, following promising preclinical data for PORT-7, a selective Adenosine A2B receptor inhibitor, given as a single agent or in combination with anti-PD-1 antibody in a murine model of mesothelioma.- Published at
- by gurufocus.com
negativenegativeSensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
”“ Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with- Published at
- by zacks.com
neutralneutralWhat Makes Sensei Biotherapeutics (SNSE) a New Buy Stock
Sensei Biotherapeutics (SNSE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).- Published at
- by manilatimes.net
negativenegative- Published at
- by gurufocus.com
negativenegativeSensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. ( SNSE), a clinical stage biotechnology company focused on the discovery and developmen- Published at
- by manilatimes.net
neutralneutral- Published at
- by manilatimes.net
negativenegative- Published at
- by benzinga.com
mixedmixedWhy iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - iRhythm Technologies (NASDAQ:IRTC)
Shares of iRhythm Technologies, Inc. IRTC rose sharply in today's pre-market trading after the company announced that it was granted FDA clearance for its 510(k...- Published at
- by investing.com
mixedmixedSensei Biotherapeutics names new financial chief By Investing.com
Sensei Biotherapeutics names new financial chief- Published at
- by globenewswire.com
neutralneutralSensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing...- Published at
- by marketscreener.com
positivepositiveASCO 2024: Topline SNS-101 Dose Escalation Data
SNS-101 Topline Monotherapy & Combination Dose Escalation Data June 3, 2024 Presenters: ...- Published at
- by marketscreener.com
positivepositiveSensei Biotherapeutics : Company Presentation June 2024
Conditionally Active Antibodies for Immuno-oncology Corporate Deck | June 2024 Disclaimer This presentation...- Published at
- by globenewswire.com
negativenegativeSensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery...- Published at
- by globenewswire.com
mixedmixedCervical Dysplasia Market Size and Share to Rise by 2032, Assesses DelveInsight | Key Companies - GlaxoSmithKline, Merck, Frantz Viral, Brooklyn ImmunoTherapeutics, PapiVax, Inovio
The cervical dysplasia market is expected to grow significantly owing to an increased screening rate and increasing initiatives to create public awareness....- Published at
- by globenewswire.com
mixedmixedCervical Cancer Market Size is Likely to Increase, Examines DelveInsight | Key Companies in the Market - Gilead, Roche, Genentech, Iovance, Bristol-Myers Squibb, Exelixis, Xencor, Merck, EMD Serono, P
The cervical cancer market is expected to grow due to factors like an increase in the patient pool, rising awareness of the disease, an increase in...